2 active not recruiting, 1 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Stage III Gastric Cancer AJCC v7: new trials by email Literature Review of Stage III Gastric Cancer AJCC v7 trials Research Report on Stage III Gastric Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Questionnaire Administration, Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Recruiting | Alliance for Clinical Trials in Oncology | 2000 | 2022-08-18 | 2026-10-02 | |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
| Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Epstein-Barr Virus Positive, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 40 | 2017-09-29 | 2026-01-20 |
| Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2016-02-01 | 2026-09-15 |
Stomach Neoplasms (4) · Esophageal Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1)
Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Neoplasms (4) · Neoplasms by Site (4) · Stomach Diseases (4) · Esophageal Diseases (3) · Head and Neck Neoplasms (3) · Colonic Diseases (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Rectal Diseases (2) · Adenocarcinoma (1) · Bone Marrow Diseases (1)
Capecitabine (1) · Radiotherapy (1) · Radiotherapy, Intensity-Modulated (1) · Ramucirumab (1) · olaparib (1) · pembrolizumab (1) · ropidoxuridine (1)
National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Rutgers, The State University of New Jersey (1)
United States (4)
Marie Wood, MD (1) · Michael Cecchini (1) · Salma Jabbour (1) · Timothy J Kinsella (1)
P30CA072720 (1), UG1CA189823 (1), UM1CA186689 (1)